-
Je něco špatně v tomto záznamu ?
Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey
A Linhart, C Kampmann, JL Zamorano, G Sunder-Plassmann, M Beck, A Mehta, PM Elliott, FOS Investigators European
Jazyk angličtina Země Velká Británie
Typ dokumentu multicentrická studie
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
PubMed
17483538
DOI
10.1093/eurheartj/ehm153
Knihovny.cz E-zdroje
- MeSH
- alfa-galaktosidasa terapeutické užití MeSH
- dospělí MeSH
- dyspnoe epidemiologie etiologie MeSH
- echokardiografie MeSH
- Fabryho nemoc farmakoterapie komplikace MeSH
- financování organizované MeSH
- hodnoty glomerulární filtrace MeSH
- hypertrofie levé komory srdeční epidemiologie komplikace MeSH
- izoenzymy terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- nemoci srdce epidemiologie komplikace MeSH
- prevalence MeSH
- rizikové faktory MeSH
- synkopa epidemiologie etiologie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
AIMS: Anderson-Fabry disease (AFD) is an uncommon X-linked disorder caused by deficient activity of the lysosomal enzyme alpha-galactosidase A. The Fabry Outcome Survey is a European database designed to monitor the long-term efficacy and safety of enzyme replacement therapy (ERT) with agalsidase alfa. The aim of this study was to determine the prevalence and characteristics of cardiac disease in AFD patients. METHODS AND RESULTS: Clinical and laboratory data were available in 714 patients from 11 countries (mean age 35 +/- 17 years, 369 women, 336 treated). The prevalence of angina was 23 vs. 22%; palpitations and arrhythmias 27 vs. 26%; exertional dyspnoea 23 vs. 23%; and syncope 2 vs. 4%, in women and men, respectively (all P = NS). The frequency of all cardiac symptoms was significantly higher in treated than in untreated patients. Gender, age, and glomerular filtration rate were independent determinants of echocardiographically assessed left ventricular hypertrophy (LVH). CONCLUSION: This study confirms the high prevalence of cardiac morbidity associated with AFD. The disease burden in treated women exceeds that of untreated men, suggesting that most women selected for ERT have advanced disease. The presence of LVH is associated with higher frequency of cardiac signs and symptoms and relates independently to gender, age, and renal function.
2nd Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 03526naa 2200577 a 4500
- 001
- bmc10010885
- 003
- CZ-PrNML
- 005
- 20171116090648.0
- 008
- 100507s2007 xxk e eng||
- 009
- AR
- 024 __
- $a 10.1093/eurheartj/ehm153 $2 doi
- 035 __
- $a (PubMed)17483538
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Linhart, Aleš, $d 1964- $7 mzk2003188958
- 245 10
- $a Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey / $c A Linhart, C Kampmann, JL Zamorano, G Sunder-Plassmann, M Beck, A Mehta, PM Elliott, FOS Investigators European
- 314 __
- $a Second Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic. alinh@lf1.cuni.cz
- 520 9_
- $a AIMS: Anderson-Fabry disease (AFD) is an uncommon X-linked disorder caused by deficient activity of the lysosomal enzyme alpha-galactosidase A. The Fabry Outcome Survey is a European database designed to monitor the long-term efficacy and safety of enzyme replacement therapy (ERT) with agalsidase alfa. The aim of this study was to determine the prevalence and characteristics of cardiac disease in AFD patients. METHODS AND RESULTS: Clinical and laboratory data were available in 714 patients from 11 countries (mean age 35 +/- 17 years, 369 women, 336 treated). The prevalence of angina was 23 vs. 22%; palpitations and arrhythmias 27 vs. 26%; exertional dyspnoea 23 vs. 23%; and syncope 2 vs. 4%, in women and men, respectively (all P = NS). The frequency of all cardiac symptoms was significantly higher in treated than in untreated patients. Gender, age, and glomerular filtration rate were independent determinants of echocardiographically assessed left ventricular hypertrophy (LVH). CONCLUSION: This study confirms the high prevalence of cardiac morbidity associated with AFD. The disease burden in treated women exceeds that of untreated men, suggesting that most women selected for ERT have advanced disease. The presence of LVH is associated with higher frequency of cardiac signs and symptoms and relates independently to gender, age, and renal function.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a dyspnoe $x epidemiologie $x etiologie $7 D004417
- 650 _2
- $a echokardiografie $7 D004452
- 650 _2
- $a Fabryho nemoc $x farmakoterapie $x komplikace $7 D000795
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hodnoty glomerulární filtrace $7 D005919
- 650 _2
- $a nemoci srdce $x epidemiologie $x komplikace $7 D006331
- 650 _2
- $a nemoci srdce $7 D006331
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypertrofie levé komory srdeční $x epidemiologie $x komplikace $7 D017379
- 650 _2
- $a izoenzymy $x terapeutické užití $7 D007527
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a synkopa $x epidemiologie $x etiologie $7 D013575
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a alfa-galaktosidasa $x terapeutické užití $7 D000519
- 650 _2
- $a financování organizované $7 D005381
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Kampmann, Christoph
- 700 1_
- $a Zamorano, Jose L
- 700 1_
- $a Sunder-Plassmann, Gere
- 700 1_
- $a Beck, Michael
- 700 1_
- $a Mehta, Atul
- 700 1_
- $a Elliott, Perry $7 xx0218791
- 773 0_
- $t European Heart Journal $w MED00009622 $g Roč. 28, č. 10 (2007), s. 1228-1235 $x 0195-668X
- 910 __
- $a ABA008 $b x $y 8 $z 0
- 990 __
- $a 20100524100406 $b ABA008
- 991 __
- $a 20171116090800 $b ABA008
- 999 __
- $a ok $b bmc $g 724742 $s 587889
- BAS __
- $a 3
- BMC __
- $a 2007 $b 28 $c 10 $d 1228-1235 $i 0195-668X $m European heart journal $n Eur Heart J $x MED00009622
- LZP __
- $a 2010-B2/dkme